30 October 2020
Latham & Watkins Advises Underwriters in Mirati Therapeutics, Inc.’s US$800 Million Public Offering of Common Stock
Advising firms
Deal team
11 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Cheston Larson Lead | Latham & Watkins LLP | Partner | capital markets | San Diego |
| Matt Bush Lead | Latham & Watkins LLP | Partner | capital markets | San Diego |
| Anthony Gostanian | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Michael Johnson | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Irene Fedoseienko | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Elizabeth Richards | Latham & Watkins LLP | Partner | regulatory | Washington, D.C. |
| Nicole Liffrig Molife | Latham & Watkins LLP | Counsel | regulatory | Not stated |
| Chad Jennings | Latham & Watkins LLP | Associate | regulatory | Not stated |
| Margaret Rote | Latham & Watkins LLP | Associate | regulatory | Not stated |
| Chris Hazuka | Latham & Watkins LLP | Partner | IP | San Diego |
| Brendan Haberle | Latham & Watkins LLP | Associate | IP | Not stated |
Stated terms
- Stated value
- USD 800m (US$800 million)
- What the figure measures
- Issue size
- Client
- Mirati Therapeutics, Inc.Issuer
- Counterparties
- underwriters (Underwriters)